EQT VIII to Acquire Majority Interest in Aldevron
July 31, 2019
EQT VIII has entered into an agreement to acquire a majority interest in Aldevron, a Fargo-based global supplier of plasmid DNA and other biologics, with founders, management and TA Associates retaining minority stakes. EQT will support Aldevron's growth through investments in production capacity, R&D and international expansion as the company continues to serve the gene therapy and broader biopharma markets.
- Buyers
- EQT (EQT VIII Fund)
- Targets
- Aldevron
- Sellers
- TA Associates
- Industry
- Biotechnology
- Location
- North Dakota, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Danaher Acquires Aldevron for $9.6 Billion
June 17, 2021
Biotechnology
Danaher Corporation entered into a definitive agreement to acquire Aldevron from EQT Private Equity for an enterprise value of approximately USD 9.6 billion. Aldevron, headquartered in Fargo, North Dakota with ~600 employees and additional operations in Madison, Wisconsin, will operate as a standalone company within Danaher's Life Sciences segment to expand Danaher's capabilities in genomic medicine and biologics manufacturing.
-
Deveron Acquires 67% Stake in A&L Canada Laboratories
May 2, 2022
Agriculture
Deveron Corp. has agreed to acquire a 67% equity interest in A&L Canada Laboratories East, Inc. for $50.3 million (cash and shares), with an option to acquire the remaining 33% after three years. The acquisition expands Deveron's lab capacity and agronomy capabilities, creating a vertically integrated agriculture data company headquartered in Canada and increasing pro forma revenue to $35.3 million.
-
EQT Acquires Majority Stake in Ellab from IK Investment Partners
August 7, 2019
Medical Devices
EQT Mid Market Europe has agreed to acquire a majority interest in Ellab A/S from the IK VIII Fund (advised by IK Investment Partners). EQT will partner with Ellab's management, which will retain a minority stake, to accelerate global growth by expanding R&D, enhancing the go-to-market model in the US and Europe, and growing the company's as-a-service offerings.
-
Arcline Investment Management Acquires Majority Interest in Akron Biotechnology
September 11, 2019
Biotechnology
Arcline Investment Management has acquired a majority interest in Akron Biotechnology LLC, a supplier of cGMP-compliant materials and services for cell and gene therapy manufacturers. Akron will remain led by founder and CEO Dr. Claudia Zylberberg, and Arcline plans to expand Akron's manufacturing capacity and pursue complementary acquisitions to build a platform in regenerative medicine.
-
Novo Nordisk Acquires Cardior Pharmaceuticals from EQT Life Sciences
March 25, 2024
Biotechnology
Novo Nordisk has agreed to acquire Cardior Pharmaceuticals for up to EUR 1.025 billion, including an upfront payment and contingent development and commercial milestone payments. Cardior, a Hannover-based clinical-stage biotech focused on RNA-targeted therapies for cardiovascular disease, is currently majority-backed by EQT Life Sciences; the deal is expected to close in Q2 2024 subject to regulatory approvals.
-
Alcon Acquires Majority Interest in Aurion Biotech, Inc.
March 26, 2025
Biotechnology
Alcon has acquired a majority interest in clinical-stage Aurion Biotech to accelerate development and commercialization of Aurion's allogeneic corneal cell therapy AURN001. Aurion will remain a separate company while leveraging Alcon's global R&D, regulatory and commercial capabilities to advance AURN001 into U.S. Phase 3 development in the second half of 2025.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.